In Brief: InControl
This article was originally published in The Gray Sheet
Executive SummaryInControl: Announces first implantation of its Metrix 3020 atrial defibrillator at the Universitair Ziekenhuis Gent in Ghent, Belgium. The 3020 incorporates "a new waveform which allows the device to deliver up to a maximum of six joules of energy," compared to the three joule capability of the firm's first-generation Metrix 3000. Early clinical study data comparing the two waveforms have demonstrated that the 3020 waveform "results in improved patient tolerance at similar defibrillation thresholds," InControl states. An investigational device exemption for the 3020 was submitted to FDA the week of Aug. 26...
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.